Lifeward Ltd SEC Filings

Lifeward Ltd. shareholders approved the Lifeward Ltd. 2025 Incentive Compensation Plan on August 1, 2025. Following the Effective Date, no new awards will be granted under the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan (the 2014 Plan) and 164,129 Ordinary Shares underlying existing awards under the 2014 Plan as of the Effective Date may be reallocated to the 2025 Plan if they become available. The filing amends prior S-8 registration statements to cover those 164,129 Outstanding Shares and notes prior registrations aggregated 916,676 Ordinary Shares (post reverse splits).

Lifeward Ltd. filed a Post-Effective Amendment on Form S-8 to transfer outstanding awards from its prior ReWalk Robotics Ltd. 2014 Incentive Compensation Plan into the Lifeward Ltd. 2025 Incentive Compensation Plan following shareholder approval on August 1, 2025. There are 164,129 ordinary shares underlying outstanding awards as of the Effective Date that will be covered to the extent they become issuable under the 2025 Plan. No additional securities are being registered. The filing notes prior reverse stock splits and incorporates by reference the company’s recent reports and governing documents.

Lifeward Ltd. filed a Form S-8 to register securities under its 2025 Incentive Compensation Plan for issuance to employees, executives and directors. The filing incorporates by reference the company’s recent annual and quarterly reports and numerous current reports, and lists exhibits including plan documents, award agreement forms for Israeli and non-Israeli participants, legal opinions, consents and a directors’ and officers’ insurance disclosure. The company describes indemnification, exculpation and insurance arrangements for office holders under Israeli law and confirms it has obtained D&O insurance and indemnification agreements to the fullest extent permitted. The filing is procedural and registers equity awards under the Plan.

Lifeward Ltd. reported lower revenues and widening losses in the quarter ended June 30, 2025. Quarterly revenue was $5.7 million versus $6.7 million a year earlier, and six‑month revenue totaled $10.8 million versus $12.0 million. The company recorded a quarterly operating loss of $6.6 million and a six‑month net loss of $11.4 million. Cash and cash equivalents were $5.1 million at June 30, 2025 and total cash, cash equivalents and restricted cash were $5.5 million, with management estimating runway into the fourth quarter of 2025, raising substantial doubt about going concern.

The company recorded a $2.8 million goodwill impairment in Q2 2025 and eliminated an earnout liability. Lifeward completed multiple 2025 equity financings, including a January registered direct offering and a June public offering (4.0 million shares with warrants), and raised proceeds under an ATM program (964,118 shares sold for net proceeds of about $1.0 million). A favorable Administrative Law Judge ruling and CMS actions have established a Medicare pathway for ReWalk (HCPCS code K1007) with a lump‑sum purchase payment of $91,032, a material reimbursement development for the ReWalk product line.

Lifeward Ltd. furnished a press release announcing its financial results for the second quarter ended June 30, 2025. The company will host a conference call to discuss those results at 8:30 a.m. E.D.T. on August 14, 2025, and an archived webcast will be available at the provided link and on the company’s Investors page for 30 days. The press release is furnished as Exhibit 99.1 and the cover page interactive XBRL is provided as Exhibit 104. The filing states these materials are furnished and are not to be deemed “filed” or incorporated by reference into other securities filings. The company’s ordinary shares trade under the LFWD ticker on the Nasdaq Capital Market.

Adar Almog, identified on the form as the company’s Chief Financial Officer, received a grant of stock options under the 2025 Incentive Compensation Plan. The award covers 225,000 options with an exercise price of $0.717 per share and was recorded with a transaction date of 08/13/2025. The options vest in four equal annual installments beginning 08/13/2026 and expire on 08/13/2035, and are reported as a direct holding tied to 225,000 ordinary shares (par value NIS 1.75). The form states a price of the derivative security of $0 and notes vesting is subject to continued service.

Lifeward Ltd. appointed Almog Adar as its Chief Financial Officer, effective August 1, 2025. Mr. Adar, age 42, is an internal promotion from Vice President of Finance and Chief Accounting Officer and will continue as the company’s principal accounting officer.

His compensation package includes an annual base salary of $315,000, an annual performance bonus opportunity of up to 35% of base salary, a one-time retention payment of $80,000 (paid in two installments), eligibility for an additional prorated 7% bonus for 2025, and a grant of options to purchase 225,000 ordinary shares vesting in four equal annual installments. Termination protections include six months salary continuation (longer for a change of control), target bonus continuation, health premium reimbursement, and accelerated vesting on certain change-of-control terminations. The agreement includes non-solicitation, non-competition and indemnification provisions.

Lifeward Ltd. received a notification from The Nasdaq Stock Market that its closing bid price has been below the required minimum of $1.00 per share for the last 30 consecutive business days. The notice is a deficiency, not a delisting, and does not currently affect the listing or trading of the companys ordinary shares.

The company has 180 days to regain compliance, until February 2, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Lifeward may be eligible for a second 180-day cure period if, as of that date, it has a market value of publicly held shares of at least $1 million, meets other initial listing standards except the bid price requirement, and provides written notice of its intent to cure.

Management states it will monitor the closing bid price and consider plans to regain compliance but expressly warns there is no assurance it will be able to do so within the cure period or any extension. The report includes customary forward-looking statements and refers readers to the companys SEC filings for additional risk factors.

Form 4 filing for Lifeward Ltd. (LFWD) discloses one routine equity award to non-executive director Randel Richner.

• Transaction: On 01-Aug-2025 the director received 35,920 restricted stock units (RSUs) of ordinary shares (par NIS 1.75) at $0 cost.
• Vesting schedule: RSUs vest in four equal quarterly instalments beginning three months after the grant date.
• Post-grant holdings: Richner now indirectly owns 57,487 shares through the company ESOP.
• No derivative securities, sales, or open-market purchases were reported.

The filing reflects standard board compensation intended to align director interests with shareholders. The modest share count suggests immaterial dilution at the company level and no immediate cash impact.